Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150210 | 1.00 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7917122 | 0.99 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7913240 | 0.95 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7911578 | 0.93 | BCL2 (0.35) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7911557 | 0.93 | FFAR1 (0.35) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7903224 | 0.93 | CYP19A1 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL7917118 | 0.93 | ROCK2 (0.34) | ROCK2TP53SMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL7913269 | 0.91 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL3209182 | 0.87 | FFAR1 (0.34) | ROCK2TP53PKMNFKB1NFKB2 | |
| SCHEMBL795594 | 0.87 | ROCK2 (0.34) | ROCK2TP53PKMNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | REMD BIOTHERAPEUTICS INC (US) | 2026-04-21 | — | — | US | disclosed |
| CN-111405899-B | Combination of 4-pyrimidine sulfonamide derivatives with SGLT-2 inhibitors for the treatment of endothelin related disorders | 爱杜西亚药品有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-17 | — | — | US | disclosed |
| EP-3716979-B1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-09 | — | — | EP | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12144811-B2 | Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-11-19 | — | — | US | disclosed |
| WO-2023225492-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023220930-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS CROSS-REFERENCES TO RELATED APPLICATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230212300-A1 | HUMAN ENDOTHELIN RECEPTOR A (ETAR) ANTAGONIST ANTIBODIES | REMD BIOTHERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-11446376-B2 | Methods for treating heart failure using glucagon receptor antagonistic antibodies | REMD BIOTHERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | EDNRA, EDNRB, FCGR2A | ROCK2 2954/4885TP53 3229/4885PKM 4046/4885 |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | ROCK2 3434/4885TP53 4511/4885PKM 580/4885 |
| US-12144811-B2 | Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseases | SLC5A2, SLC5A1, GLP1R | ROCK2 2985/4885TP53 4447/4885PKM 1385/4885 |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | SLC5A2, SLC5A1, GLP1R | ROCK2 2985/4885TP53 4447/4885PKM 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.